- Report
- May 2024
- 137 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Report
- May 2024
- 128 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Report
- May 2024
- 138 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Report
- May 2024
- 135 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Report
- May 2024
- 128 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Report
- May 2024
- 140 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Report
- May 2024
- 138 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Report
- May 2024
- 137 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Report
- May 2024
- 140 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Report
- July 2024
- 150 Pages
Global
From €3579EUR$3,750USD£2,999GBP
- Report
- May 2024
- 298 Pages
Global
From €7587EUR$7,950USD£6,357GBP
- Report
- March 2025
- 450 Pages
Global
From €4772EUR$5,000USD£3,998GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1909EUR$2,000USD£1,599GBP
- Clinical Trials
- April 2024
- 115 Pages
Global
From €1909EUR$2,000USD£1,599GBP
- Drug Pipelines
- April 2024
- 230 Pages
Global
From €2863EUR$3,000USD£2,399GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1909EUR$2,000USD£1,599GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1432EUR$1,500USD£1,199GBP
- Clinical Trials
- April 2024
- 50 Pages
Global
From €1432EUR$1,500USD£1,199GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1193EUR$1,250USD£1,000GBP
- Drug Pipelines
- April 2024
- 60 Pages
Global
From €1193EUR$1,250USD£1,000GBP

Pembrolizumab is a type of oncology drug used to treat certain types of cancer. It is a monoclonal antibody, which works by targeting and blocking a protein called PD-1, which is found on the surface of some cancer cells. This helps the body's immune system to recognize and attack the cancer cells. Pembrolizumab is used to treat a variety of cancers, including melanoma, non-small cell lung cancer, head and neck cancer, Hodgkin lymphoma, and urothelial carcinoma. It is also used in combination with other drugs to treat certain types of advanced or metastatic cancers.
Pembrolizumab is approved by the US Food and Drug Administration (FDA) and is available in the US and other countries. It is typically administered intravenously, and the dosage and duration of treatment depend on the type and stage of cancer being treated.
Some companies in the Pembrolizumab market include Merck & Co., Inc., Bristol-Myers Squibb, AstraZeneca, and Roche. Show Less Read more